1 citations
,
June 2018 in “International Journal of Dermatology” DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
248 citations
,
December 2011 in “Journal of Neuroscience” Neurosteroids are crucial for stress response, and targeting specific receptors may help treat certain disorders.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
July 2022 in “Journal of Investigative Dermatology” Cyclohexyl salicylate promotes human hair growth and increases certain hair follicle stem cell progeny.
35 citations
,
January 2006 in “Cancer Research” Mice with extra PKCδ resist chemical-induced skin cancer but not UV-induced.
105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.
9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.
15 citations
,
March 2023 in “Heliyon” Beehive extracts may help with anxiety, depression, and inflammation.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
January 2008 in “OhioLink ETD Center (Ohio Library and Information Network)” SARMs work differently in tissues due to unique interactions and structures.
July 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.
45 citations
,
March 2020 in “International Journal of Nanomedicine” Clove essential oil nanoemulgel effectively reduces skin inflammation and is a promising alternative to traditional anti-inflammatory drugs.
14 citations
,
May 2019 in “Human gene therapy” MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
1 citations
,
March 2020 in “Journal of Pharmacological Sciences” Benzothiazepines like diltiazem reduce anxiety in mice by making neurosteroids.
431 citations
,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
11 citations
,
May 2010 in “Journal of Medicinal Chemistry” A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.
June 2008 in “Alcoholism Clinical and Experimental Research” Certain drugs can block changes in brain receptors caused by alcohol withdrawal.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
A new method creates valuable compounds for drug discovery by breaking traditional chemical rules.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
31 citations
,
October 2019 in “Genes & Diseases” Basal cell carcinomas and squamous cell carcinomas have different gene activity patterns, suggesting unique treatment approaches.